Angiodynamics (ANGO) 13.53 $ANGO
AngioDynamics to Present at Upcoming Investor Conferences
GlobeNewswire - Tue May 06, 6:05AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today the company will present at the following investor conferences in May.
AngioDynamics Names Howard W. Donnelly Chairman of the Board of Directors
GlobeNewswire - Tue Apr 29, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced Howard W. Donnelly, 52, has been named Chairman of the Board of Directors, effective immediately.
Weakness Seen in AngioDynamics (ANGO): Stock Tumbles 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 7:43AM CDT
AngioDynamics falls 7.8% last trading session, continuing the downtrend
AngioDynamics Q3 Earnings Flat but Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:28AM CDT
ANGO lowered its adjusted EPS guidance for fiscal 2014 to a range of 60 to 63 cents from the prior range of 63 to 67 cents.
AngioDynamics Reports Fiscal 2014 Third Quarter Financial Results
GlobeNewswire - Wed Apr 09, 3:01PM CDT
-- Net sales increase 8% over prior year to $88.2 million
AngioDynamics to Report Fiscal 2014 Third Quarter Financial Results
GlobeNewswire - Tue Mar 25, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 third quarter financial results for the period ended February 28, 2014, on Wednesday, April 9, 2014, after the close of the U.S. financial markets.
AngioDynamics Awarded $74.9 Million in Case Against biolitec AG
GlobeNewswire - Thu Mar 20, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced a recent court action in its legal case against biolitec AG.
FDA Expands Angiovac Clearance for AngioDynamics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 17, 10:42AM CDT
The expanded clearance for AngioVac cannula seems reasonable given the wide acceptance of the product across the U.S.
AngioDynamics Raised to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 11:00AM CDT
A promising guidance, an innovative pipeline and management's efforts to leverage operational activities represent a potential upside for AngioDynamics going forward.
AngioDynamics (ANGO) in Focus: Stock Moves 5.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:18AM CDT
AngioDynamics Inc. (ANGO) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Wednesday's Top Upgrades (and Downgrades)
Rich Smith, The Motley Fool - Motley Fool - Wed Mar 12, 11:00AM CDT
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature downgrades for clothiers Urban Outfitters and American Eagle Outfitters . But...
Upgrade Alert for Angiodynamics (ANGO)
Comtex SmarTrend(R) - Wed Mar 12, 7:05AM CDT
Angiodynamics (NASDAQ:ANGO) was upgraded from Market Perform to Outperform at Raymond James today. The stock closed yesterday at $15.85 on volume of 175,000 shares, above average daily volume of 146,000. AngioDynamics, Inc. designs, develops, manufactures, and markets therapeutic and diagnostic devices. The Company's products enable interventional physicians to treat peripheral vascular disease and other non-coronary diseases. AngioDynamic's product lines consist of angiographic catheters, hemodialysis catheters, image guided vascular access products, and thrombolytic products.
AngioDynamics Receives Expanded FDA Clearance for AngioVac
GlobeNewswire - Tue Mar 11, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded indication for its AngioVac cannula for venous drainage during extracorporeal bypass for up to six hours to include removal of fresh, soft thrombi or emboli.
AngioDynamics Gets 3rd FDA Approval for BioFlo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 4:30PM CDT
The commercial launch of the catheter, which is expected in the fourth quarter of fiscal year 2014, is likely to boost ANGO's 15% share in the $100 million chronic dialysis catheter market.
AngioDynamics Receives FDA Clearance for DuraMax Dialysis Catheter With BioFlo Technology to Reduce Catheter-Related Thrombus
GlobeNewswire - Fri Mar 07, 5:30AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration granted 510(k) clearance for its BioFlo DuraMax chronic hemodialysis catheter.
AngioDynamics Updates U.S. Tip Location Strategy
GlobeNewswire - Fri Mar 07, 2:59AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) rejected its distribution partner, Medcomp Inc.'s, 510(k) application for the Celerity tip location system.
Coverage on Covance Initiated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:20PM CST
On Mar 06, 2014, we initiated coverage on Covance.
Cyberonics Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:10PM CST
On Feb 26, 2014, Zacks Investment Research upgraded Cyberonics Inc. to a Zacks Rank #2 (Buy).
AngioDynamics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 03, 6:00AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo, President and Chief Executive Officer, is scheduled to address the Barclays Global Healthcare Conference on Tuesday, March 11, 2014, at 4:15 p.m. ET. The conference will be held at the Loews Hotel in Miami, Fla.
BioScrip Down on Q4 Loss, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:30AM CST
BioScrip recently declared its fourth-quarter 2013 results.
AngioDynamics to Present at Upcoming Investor Conferences
GlobeNewswire - Tue May 06, 6:05AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today the company will present at the following investor conferences in May.
AngioDynamics Names Howard W. Donnelly Chairman of the Board of Directors
GlobeNewswire - Tue Apr 29, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced Howard W. Donnelly, 52, has been named Chairman of the Board of Directors, effective immediately.
Weakness Seen in AngioDynamics (ANGO): Stock Tumbles 7.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 7:43AM CDT
AngioDynamics falls 7.8% last trading session, continuing the downtrend
AngioDynamics Q3 Earnings Flat but Beat Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:28AM CDT
ANGO lowered its adjusted EPS guidance for fiscal 2014 to a range of 60 to 63 cents from the prior range of 63 to 67 cents.
AngioDynamics Reports Fiscal 2014 Third Quarter Financial Results
GlobeNewswire - Wed Apr 09, 3:01PM CDT
-- Net sales increase 8% over prior year to $88.2 million
AngioDynamics to Report Fiscal 2014 Third Quarter Financial Results
GlobeNewswire - Tue Mar 25, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report its fiscal 2014 third quarter financial results for the period ended February 28, 2014, on Wednesday, April 9, 2014, after the close of the U.S. financial markets.
AngioDynamics Awarded $74.9 Million in Case Against biolitec AG
GlobeNewswire - Thu Mar 20, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced a recent court action in its legal case against biolitec AG.
FDA Expands Angiovac Clearance for AngioDynamics - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 17, 10:42AM CDT
The expanded clearance for AngioVac cannula seems reasonable given the wide acceptance of the product across the U.S.
AngioDynamics Raised to Hold - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 11:00AM CDT
A promising guidance, an innovative pipeline and management's efforts to leverage operational activities represent a potential upside for AngioDynamics going forward.
AngioDynamics (ANGO) in Focus: Stock Moves 5.7% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 8:18AM CDT
AngioDynamics Inc. (ANGO) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Wednesday's Top Upgrades (and Downgrades)
Rich Smith, The Motley Fool - Motley Fool - Wed Mar 12, 11:00AM CDT
This series, brought to you by Yahoo! Finance, looks at which upgrades and downgrades make sense, and which ones investors should act on. Today, our headlines feature downgrades for clothiers Urban Outfitters and American Eagle Outfitters . But...
Upgrade Alert for Angiodynamics (ANGO)
Comtex SmarTrend(R) - Wed Mar 12, 7:05AM CDT
Angiodynamics (NASDAQ:ANGO) was upgraded from Market Perform to Outperform at Raymond James today. The stock closed yesterday at $15.85 on volume of 175,000 shares, above average daily volume of 146,000. AngioDynamics, Inc. designs, develops, manufactures, and markets therapeutic and diagnostic devices. The Company's products enable interventional physicians to treat peripheral vascular disease and other non-coronary diseases. AngioDynamic's product lines consist of angiographic catheters, hemodialysis catheters, image guided vascular access products, and thrombolytic products.
AngioDynamics Receives Expanded FDA Clearance for AngioVac
GlobeNewswire - Tue Mar 11, 5:30AM CDT
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) cleared an expanded indication for its AngioVac cannula for venous drainage during extracorporeal bypass for up to six hours to include removal of fresh, soft thrombi or emboli.
AngioDynamics Gets 3rd FDA Approval for BioFlo - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 4:30PM CDT
The commercial launch of the catheter, which is expected in the fourth quarter of fiscal year 2014, is likely to boost ANGO's 15% share in the $100 million chronic dialysis catheter market.
AngioDynamics Receives FDA Clearance for DuraMax Dialysis Catheter With BioFlo Technology to Reduce Catheter-Related Thrombus
GlobeNewswire - Fri Mar 07, 5:30AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration granted 510(k) clearance for its BioFlo DuraMax chronic hemodialysis catheter.
AngioDynamics Updates U.S. Tip Location Strategy
GlobeNewswire - Fri Mar 07, 2:59AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the U.S. Food and Drug Administration (FDA) rejected its distribution partner, Medcomp Inc.'s, 510(k) application for the Celerity tip location system.
Coverage on Covance Initiated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 2:20PM CST
On Mar 06, 2014, we initiated coverage on Covance.
Cyberonics Upped to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 2:10PM CST
On Feb 26, 2014, Zacks Investment Research upgraded Cyberonics Inc. to a Zacks Rank #2 (Buy).
AngioDynamics to Present at the Barclays Global Healthcare Conference
GlobeNewswire - Mon Mar 03, 6:00AM CST
AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, announced today that Joseph M. DeVivo, President and Chief Executive Officer, is scheduled to address the Barclays Global Healthcare Conference on Tuesday, March 11, 2014, at 4:15 p.m. ET. The conference will be held at the Loews Hotel in Miami, Fla.
BioScrip Down on Q4 Loss, Poor Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 10:30AM CST
BioScrip recently declared its fourth-quarter 2013 results.
